Research programme: plasma-derived biopharmaceuticals - ProMetic Life Sciences

Drug Profile

Research programme: plasma-derived biopharmaceuticals - ProMetic Life Sciences

Alternative Names: Alpha-1 antitrypsin deficiency therapy - ProMetic Life Sciences; C1 INH - ProMetic Life Sciences; Haemophilia therapeutics - ProMetic Life Sciences; Plasma-derived orphan drug products - ProMetic Life Sciences

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProMetic Life Sciences
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Alpha 1-antitrypsin replacements; Blood coagulation stimulants; Complement C1 inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hereditary angioedema
  • Research Haemophilia
  • No development reported Alpha 1-antitrypsin deficiency

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in Canada (Parenteral)
  • 21 Jun 2017 Preclinical trials in Hereditary angioedema in Canada before June 2017 (ProMetic Life Sciences pipeline, June 2017)
  • 21 Jun 2017 ProMetic Life Sciences plans to file an IND application with the US FDA in Hereditary angioedema in 2017 (ProMetic Life Sciences pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top